Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. How to Source Non-IMP Supplies for Clinical Trials
  2. Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
  3. How Whole Systems Thinking Could Transform the Clinical Supply Chain
  4. Integrating New Assets: A Supply Chain Perspective
  5. The Dawn of Cell Therapies, Blockchain, and M&A: Industry Trends in the CMO Landscape

Latest Content

IoT Tracking and Monitoring

Cell and gene therapy shipments involve a complex sequence of events with precise planning and coordination of the stakeholders involved. The medicines are unique and have vulnerable characteristics.

June’s top news stories

AstraZeneca’s human monoclonal antibody Imfinzi (durvalumab) improved overall survival in the Phase III CASPIAN trial in first-line extensive-stage small cell lung cancer (SCLC).

May’s top news stories

Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The National Institute of Allergy and Infectious Diseases (NIAID) has reported findings from a Phase I/II clinical trial of Okairos’ AdCh3NSmut1/MVA-NSmut vaccine. wraps up the key headlines from May 2019.

February’s top news stories

Eidos Therapeutics commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), and Immatics is set to study its investigational therapy IMA101 in combination with Roche’s Tecentriq (atezolizumab) drug for the treatment of solid cancers. wraps up key headlines from February 2019.

Latest News


Go Top